Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Johnson & Johnson Suspends Sales Forecast For COVID-19 Vaccine, Trims FY22 Profit Outlook

Johnson & Johnson (NYSE:JNJ) has reported Q1 FY22 adjusted earnings of $2.67 per share, up 3.1% Y/Y and ahead of the consensus of $2.61. Net sales increased 5% Y/Y (7.9% on an operational basis) to $23.43 billion, missing the consensus of $23.67 billion. Pharmaceuticals contributed $12.87 billion in sales, +9.3%, due to Darzalex…

Benzinga

Recap: Johnson & Johnson Q1 Earnings

Johnson & Johnson (NYSE:JNJ) reported its Q1 earnings results on Tuesday, April 19, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

J&J's Janssen settles with WVa for $99M in opioid lawsuit

West Virginia will receive $99 million in a settlement finalized with Johnson & Johnson’s subsidiary Janssen Pharmaceuticals Inc. The state filed a lawsuit accusing the drugmaker of contributing to the opioid crisis in the state that's led the nation in overdose deaths

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Outlook For Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is set to give its latest quarterly earnings report on Tuesday, 2022-04-19. Here's what investors need to know before the announcement. Analysts estimate that Johnson & Johnson will report an earnings per share (EPS) of $2.61.

Benzinga

5 Stocks to Buy for Stable Income in a Volatile Market

Because concerns over high inflation and increasing sanctions on Russia are expected to fuel stock market volatility in the near term, we think it could be wise to bet on dividend aristocrats Johnson & Johnson (JNJ), Procter & Gamble (PG), PepsiCo (PEP), Abbott (ABT), and Becton Dickinson (BDX) for a…

StockNews.com

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

StockNews.com

4 Dividend Aristocrats to Buy in February

Rising inflation and the Fed’s signal that it will raise interest rates multiple times this year fostered high market volatility last month. And although the major market indexes rose for the third consecutive trading session yesterday, many analysts expect the market to remain volatile this year. Given this backdrop, we…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Best Dividend Kings for Decades of Dividend Growth

Dividend Kings are the crème de la crème of dividend growers and should be top of mind for any investor who puts income stability above all else.

Kiplinger

The Kiplinger Dividend 15: Our Favorite Dividend-Paying Stocks

The Kiplinger Dividend 15 are poised to benefit as falling interest rates lure investors back to dividend-paying stocks.

Kiplinger

2 FB OR NOT 2 FB

How do you plan your day? What you intend to do with your time? Where do you go? What do you eat? The thousands of tiny, daily, decisions of living your life: brush teeth, shower, wear nice clothes, go to work, go out for dinner, shop on the weekends, for…

Newslaundry

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.